SEC, DOJ sub­poe­na Bio­gen over Aduhelm launch and for­eign busi­ness op­er­a­tions

Adding to the mul­ti­ple in­ves­ti­ga­tions in­to Bio­gen and its con­tro­ver­sial Alzheimer’s drug Aduhelm since its ap­proval, the com­pa­ny re­vealed in SEC fil­ings on Wednes­day that it has been sub­poe­naed by both the Se­cu­ri­ties and Ex­change Com­mis­sion and the De­part­ment of Jus­tice.

Ac­cord­ing to Bio­gen, the SEC is­sued a sub­poe­na for in­for­ma­tion re­lat­ed to Aduhelm and its launch, while the DOJ wants in­for­ma­tion on the com­pa­ny’s “busi­ness op­er­a­tions in sev­er­al for­eign coun­tries.” Bio­gen said it’s al­so giv­ing in­for­ma­tion on that same top­ic to the SEC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER